
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) filed a petition Monday urging the FDA to delay approval of Aquestive Therapeutics Inc.'s (NASDAQ:AQST) experimental epinephrine treatment, citing safety, dosing, and real-world use concerns.
The filing requests that the FDA withhold approval of AQST-109, a sublingual film branded as Anaphylm. If cleared, ARS wants a boxed warning highlighting potential cardiovascular risks.